• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Unicycive Therapeutics Inc (NQ: UNCY )

    0.4551 -0.0049 (-1.07%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Unicycive Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Unicycive: This Biotech Company Receives Promising Results From New Trial
    Unicycive: This Biotech Company Receives Promising Results From New Trial 
    Via News Direct
    Unicycive: This Biotech Company Receives Promising Results From New Trial
    Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the... 
    Via Benzinga
    Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies
    Via Benzinga
    Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
    Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia 
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
    Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively 
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
    Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
    Via Benzinga
    Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
    Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the... 
    Via Benzinga
    Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
    U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Wednesday. 
    Via Benzinga
    Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Dow Tumbles 150 Points; Crude Oil Falls Sharply
    U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday. 
    Via Benzinga
    Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study
    Via Benzinga
    Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
    Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023 
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
    Via ACCESSWIRE
    Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
    In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
    Via Benzinga
    Unicycive to Participate in Upcoming Investor Conferences
    Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction 
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Announces Third Quarter Financial Results and Provides Business Update
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Gainers 
    Via Benzinga
    Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
    You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
    Via TheNewswire.com
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.